Chapter-33 Uterine Malignancy

BOOK TITLE: Essentials of Gynecology

1. Arulkumaran Sabaratnam
2. Mukhopadhyay Sambit
3. Ahuja Sapna
Publishing Year
Author Affiliations
1. St. George’s Hospital Medical School London, St. George’s Hospital Medical School, London, St George’s Hospital Medical School, London, United Kingdom, St George’s Hospital Medical School, London, United Kingdom, e-mail: sarulkum@sghms.ac.uk, St George s University of London, London, UK, St George’s Hospital Medical School Cranmer Terrace, London SW17 0RE, United Kingdom, St George’s University of London, Cranmer Terrace, London, United Kingdom, FIGO; University of Nicosia, Nicosia, Cyprus
2. Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, NRS Medical College and Hospital, Kolkata), Salt Lake City, Kolkata, India, Norfolk and Norwich University Hospital, NHS Trust, Norwich, United Kingdom
3. Luton and Dunstable Hospital NHS Trust, Lewsey Road, LUTON, LU4 0EN
Chapter keywords


The advanced uterine sarcomas have a poor 2-year survival of less than 50%. The five year survival is 20-40%. Presently trials are trying to find out the optimal adjuvant treatment following surgical excision of the tumor. Surgery is the mainstay of management of endometrial cancer. Though the FIGO classification requires lymphadenectomy and histology this is unlikely to be routinely undertaken for low and medium risk patients. Adjuvant radiotherapy reduces the risk of vault recurrence but survival is not affected. The response rate of chemotherapy is generally poor. Endometrial cancer constitutes 25-30% of all gynecological malignancies. It is the commonest gynecological cancer in the United States. Nearly 25% of those affected die of the disease. Survival is about 75% for those with adenocarcinoma but is only about 50% for those with rarer types of histology like clear cell and papillary serous carcinoma.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved